Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-10-28
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices, cloud workflow software, education tools, and chip-licensing services built on its semiconductor ultrasound platform.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Real Device, Early Platform
The handheld ultrasound business looks increasingly real, but the five-year upside still depends on proving that workflow, education, and Embedded become durable revenue engines. The stock can compound well from here, though not all of the platform narrative is earned yet.

Analysis

Thesis
Butterfly is no longer just a probe story: if it converts its semiconductor ultrasound lead into governed workflow, education, and repeatable OEM licensing, revenue can scale faster than units and the business can still earn a platform-like valuation despite some multiple compression.
Last Economy Alignment
Cheaper AI should expand who can scan, where scans happen, and how much workflow automation matters; Butterfly owns a regulated device surface plus the software and partner hooks around it. The cap on upside is that larger imaging vendors can bundle similar handheld tools and hospital workflow into broader contracts.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The core handheld business is real, not hypothetical, and the main upside is quality of revenue rather than just more devices. Each new deployment can pull through memberships, education, workflow, and partner applications. If Embedded becomes repeatable instead of bespoke, investors can keep treating the company as a software-defined imaging platform rather than a small device vendor, but I still assume some valuation discipline until that proof is durable.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is conversion, not invention. Butterfly already has a credible product and improving gross margin, but the 2031 case depends on turning qualitative platform signals into repeatable revenue from workflow, government, home care, and Embedded. If those engines stay lumpy or slow, the market will likely value it more like a niche device company than a software-defined imaging platform.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.45
They control a real medical device plus the software layer around how scans are captured, stored, and governed, so cheaper AI can make more clinicians productive on their system. The risk is that bigger imaging vendors bundle similar handheld tools into hospital contracts before Butterfly turns that workflow edge into a habit.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$11.17
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case